The JAK2 V617F mutation in patients with cerebral venous thrombosis: A rebuttal

• References

• 1 Tefferi A, Thiele J, Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
• 2 Kiladjian J-J, Cervantes F, Leebeek FWG. et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood. 2008 epub ahead of print.
• 3 Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-1798.
• 4 Bazzan M, Tamponi G, Schinco P. et al. Thrombosis-free survival and life expetancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol 1999; 78: 539-543.
• 5 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
• 6 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
• 7 Bellucci S, Cassinat B, Bonnin N. et al. The V617F JAK2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008; 99: 1119-1120.